OncoMatch/Clinical Trials/NCT03949231
Infusion of PD1/PDL1/CTLA4 Inhibitors Via Hepatic Arterial for Immunotherapy of Hepatocellular Carcinoma
Is NCT03949231 recruiting? Yes, currently enrolling (Jun 2026). This Phase 3 trial studies PD1/PDL1 inhibitor for liver cancer.
Treatment: PD1/PDL1 inhibitor — This trial was designed to investigate the survival outcomes, response rates, and safety of patients with Barcelona-Clinical Hepatocellular Carcinoma (BCLC)-C-stage liver cancer by hepatic artery versus vein infusion of PD1/PDL1/CTLA4 inhibitor or their combinations.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Hepatocellular Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Demographics
Prior therapy
Cannot have received: transplantation
Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on
Cannot have received: resection
Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on
Cannot have received: radiotherapy
Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on
Cannot have received: chemotherapy
Patients have the past history of liver cancer treatment, such as transplantation, resection, radiotherapy, chemotherapy and so on
Lab requirements
Blood counts
WBC ≥ 3.0×10E9/L; Hb ≥ 90g/L; PLT ≥ 50×10E9/L; INR < 2.3 or PT < 6 seconds above control
Kidney function
Cr ≤ 145.5 umul/L; Renal failure / insufficiency requiring hemo- or peritoneal dialysis [excluded]
Liver function
Child-Pugh class A or B/Child score > 7; Albumin > 28 g/L; Total bilirubin < 51 μmol/L
Child-Pugh class A or B/Child score > 7; WBC≥3.0×10E9/L; Hb≥90g/L； PLT ≥50×10E9/L；INR < 2.3 or PT < 6 seconds above control；Cr ≤ 145.5 umul/L；Albumin > 28 g/L；Total bilirubin < 51 μmol/L; Impaired clotting test (platelet count < 60000/mm3, prothrombin activity < 50%) [excluded]; Renal failure / insufficiency requiring hemo-or peritoneal dialysis [excluded]
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT03949231 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior transplantation, resection, radiotherapy disqualifies patients from enrollment.
Is there an age limit?
Yes. Patients must be 80 years or younger.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages